Close Menu

You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.

Home » Business, Policy & Funding » Reimbursement News » Myriad Genetics' Breast Cancer Recurrence Test Refused Expanded Coverage in Draft LCDs

Myriad Genetics' Breast Cancer Recurrence Test Refused Expanded Coverage in Draft LCDs

Jun 09, 2020
|
staff reporter

NEW YORK – Two Medicare Administrative Contractors released draft local coverage determinations last week denying a request from Myriad Genetic Laboratories to expand coverage of its EndoPredict breast cancer gene expression test.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The Scan

And Maybe Not

President Donald Trump might not approve the stricter standards the US Food and Drug Administration is developing for authorizing a SARS-CoV-2 vaccine, according to Politico.

Now Onto a Hungry Caterpillar

Wired reports that Oxitec has now developed a genetically modified fall armyworm.

This Variant Here

A large genetic study finds SARS-CoV-2 viruses with a certain variant are spreading more than others, according to the Washington Post.

Nature Papers Present Tool for Topological Analysis of Chromosomes, Map of Genome-Lipid Associations

In Nature this week: sister-chromatid-sensitive chromosome conformation capture approach, and more.

Sponsorships

Privacy Policy.  Terms & Conditions.  .  Copyright © 2020 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.